6.
Gurney A, Axelrod F, Bond C, Cain J, Chartier C, Donigan L
. Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors. Proc Natl Acad Sci U S A. 2012; 109(29):11717-22.
PMC: 3406803.
DOI: 10.1073/pnas.1120068109.
View
7.
Corsello S, Nagari R, Spangler R, Rossen J, Kocak M, Bryan J
. Discovering the anti-cancer potential of non-oncology drugs by systematic viability profiling. Nat Cancer. 2020; 1(2):235-248.
PMC: 7328899.
DOI: 10.1038/s43018-019-0018-6.
View
8.
White B, Chien A, Dawson D
. Dysregulation of Wnt/β-catenin signaling in gastrointestinal cancers. Gastroenterology. 2011; 142(2):219-32.
PMC: 3285553.
DOI: 10.1053/j.gastro.2011.12.001.
View
9.
Kim J, Jeon Y, Lim S, Ryu J, Lee J, Chang I
. Akt-mediated Ephexin1-Ras interaction promotes oncogenic Ras signaling and colorectal and lung cancer cell proliferation. Cell Death Dis. 2021; 12(11):1013.
PMC: 8553951.
DOI: 10.1038/s41419-021-04332-0.
View
10.
Gomes P, Gomes D, Bernardi R
. Protein structure prediction in the era of AI: Challenges and limitations when applying to force spectroscopy. Front Bioinform. 2022; 2:983306.
PMC: 9580946.
DOI: 10.3389/fbinf.2022.983306.
View
11.
Gao Z, Seeling J, Hill V, Yochum A, Virshup D
. Casein kinase I phosphorylates and destabilizes the beta-catenin degradation complex. Proc Natl Acad Sci U S A. 2002; 99(3):1182-7.
PMC: 122164.
DOI: 10.1073/pnas.032468199.
View
12.
Amit S, Hatzubai A, Birman Y, Andersen J, Ben-Shushan E, Mann M
. Axin-mediated CKI phosphorylation of beta-catenin at Ser 45: a molecular switch for the Wnt pathway. Genes Dev. 2002; 16(9):1066-76.
PMC: 186245.
DOI: 10.1101/gad.230302.
View
13.
Behrens J, Jerchow B, Wurtele M, Grimm J, Asbrand C, Wirtz R
. Functional interaction of an axin homolog, conductin, with beta-catenin, APC, and GSK3beta. Science. 1998; 280(5363):596-9.
DOI: 10.1126/science.280.5363.596.
View
14.
Gong X, Azhdarinia A, Ghosh S, Xiong W, An Z, Liu Q
. LGR5-Targeted Antibody-Drug Conjugate Eradicates Gastrointestinal Tumors and Prevents Recurrence. Mol Cancer Ther. 2016; 15(7):1580-90.
DOI: 10.1158/1535-7163.MCT-16-0114.
View
15.
McFarland J, Ho Z, Kugener G, Dempster J, Montgomery P, Bryan J
. Improved estimation of cancer dependencies from large-scale RNAi screens using model-based normalization and data integration. Nat Commun. 2018; 9(1):4610.
PMC: 6214982.
DOI: 10.1038/s41467-018-06916-5.
View
16.
Li V, Ng S, Boersema P, Low T, Karthaus W, Gerlach J
. Wnt signaling through inhibition of β-catenin degradation in an intact Axin1 complex. Cell. 2012; 149(6):1245-56.
DOI: 10.1016/j.cell.2012.05.002.
View
17.
Naujokat C, Steinhart R
. Salinomycin as a drug for targeting human cancer stem cells. J Biomed Biotechnol. 2012; 2012:950658.
PMC: 3516046.
DOI: 10.1155/2012/950658.
View
18.
Katoh M
. Canonical and non-canonical WNT signaling in cancer stem cells and their niches: Cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review). Int J Oncol. 2017; 51(5):1357-1369.
PMC: 5642388.
DOI: 10.3892/ijo.2017.4129.
View
19.
Shamah S, Lin M, Goldberg J, Estrach S, Sahin M, Hu L
. EphA receptors regulate growth cone dynamics through the novel guanine nucleotide exchange factor ephexin. Cell. 2001; 105(2):233-44.
DOI: 10.1016/s0092-8674(01)00314-2.
View
20.
Hart M, de los Santos R, Albert I, Rubinfeld B, Polakis P
. Downregulation of beta-catenin by human Axin and its association with the APC tumor suppressor, beta-catenin and GSK3 beta. Curr Biol. 1998; 8(10):573-81.
DOI: 10.1016/s0960-9822(98)70226-x.
View